GlassScriptPhysician profile
Ashley N Parsons
NPI 1659615755
$11,344.06
in general payments reported to CMS, 2019-2025
20 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $348 · 2023: $4,550 · 2024: $3,618 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,757 · Food and Beverage: $1,506 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,756.64 |
| Food and Beverage | $1,505.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $540.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,963.90 | 2021-2025 | Nexplanon |
| Pfizer INC. | $1,036.61 | 2021-2025 | |
| Astellas Pharma US INC | $372.57 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $268.33 | 2021-2025 | |
| Exeltis, USA INC. | $138.35 | 2021-2025 | Slynd |
| Abbvie INC. | $91.65 | 2021-2024 | |
| Genzyme Corporation | $84.50 | 2024 | |
| Sage Therapeutics, LLC | $84.31 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $73.17 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $39.69 | 2025 | Cologuard Collection Kit |
| Aspira Women'S Health INC | $28.82 | 2021 | |
| Merck Sharp & Dohme LLC | $27.06 | 2021 | |
| Hologic Sales and Service, LLC | $22.42 | 2024 | Thinprep 2000 Processor, Aptima |
| Mayne Pharma Commercial LLC | $21.34 | 2023 | |
| Supernus Pharmaceuticals, INC. | $20.12 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $16.82 | 2022 | |
| Glaxosmithkline, LLC. | $15.55 | 2024 | Nucala |
| Cumberland Pharmaceuticals, INC. | $14.54 | 2022 | |
| Myovant Sciences INC. | $13.15 | 2022 | |
| Agile Therapeutics, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.